“…There are also recent confirmations on rituximab's effectiveness in non-oncological, and in particular autoimmune diseases, such as Rheumatoid arthritis (RA) (Wendler et al, 2014;Cambridge et al, 2014) [e.g. 8,9], multiple sclerosis (MS) (Castillo-Trivino et al, 2013;Palanichamy et al, 2014), systemic Lupus Erythematosus (SLE) (Olfat et al, 2014), and refractory pulmonary sarcoidosis (Sweiss et al, 2014). For instance, a study on Idiopathic thrombocytopenia purpura (ITP; as an autoimmune hematological disorder which considered by low platelet counts) showed rituximab had significant impact in elevating the platelet counts in 57% patients (Braendstrup et al, 2005).…”